Navigation Links
Physician Familiarity With Biosimilars Has Increased Significantly Over The Past Year
Date:8/28/2013

EXTON, Pa., Aug. 28, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds a significant increase in the percentage of surveyed specialists who are extremely familiar with biosimilars in 2013 compared with 2012, although this group remains a minority of all physicians.

The Biosimilars Advisory Service report entitled Acceptance of Biosimilars Across Physician Specialties provides analysis of survey results from 560 physicians across six specialties in the United States and Europe. The report finds that surveyed endocrinologists are least familiar with biosimilars, with only a minority saying they are very or extremely familiar with biosimilars compared with the majority of surveyed hematologist-oncologists across all countries. On average, hematologist-oncologists and medical oncologists report significantly higher levels of familiarity compared with nephrologists and endocrinologists. From a country perspective, surveyed physicians in Germany are significantly more familiar with biosimilars than those in France, although there has been a significant increase in familiarity among French physicians this year compared with data collected in 2012.

The majority of all surveyed physicians perceive reference brands and biosimilars to be very similar to one another. Surveyed endocrinologists view biosimilars as being least similar to the reference brand; less than one half say biosimilars are very similar to the reference brand compared with two thirds of hematologist-oncologists who feel the same. The report also quantifies the correlation between physicians' level of familiarity with biosimilars and their perception of similarity between biosimilars and their reference brands.   

"Despite the availability of biosimilar somatropin plus epoetin alfa and zeta in Europe, surveyed European endocrinologists and nephrologists remain less familiar with biosimilars compared with their oncologist colleagues, although we do see marked differences by country among surveyed nephrologists," said BioTrends Research Group Senior Director, Andrew Merron, Ph.D.  "Conversely, reflecting the good acceptance of biosimilars and the relatively high level of biosimilar filgrastim uptake, surveyed European hematologist-oncologists and medical oncologists report a high level of familiarity with biosimilars. We expect this finding will contribute to a comparatively rapid uptake of complex biosimilars among oncologists compared with other specialists."

The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Online Training Course Reduces Risk for Physician Groups
2. Medtech College Recognizes Medical Billers & Coders For "Cracking The Code" Of Insurance, Patient And Physician Billing
3. New Medical Education Program Online Helps Physicians to Make The Diagnosis of Myelodysplastic Syndrome (MDS)
4. Douglas Harrington, MD Speaks At American Academy Of Physicians Assistants 2013 Conference In Washington, DC
5. The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments
6. Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS)
7. Lisa Lorraine Reyes Muñoz, GeneCell International’s Physician Relation's Manager Launches Educational Meetings for General Public on Umbilical Cord Blood Stem Cells
8. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
9. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
10. New Obesity Education Program To Premiere At American College of Physicians (ACP) Annual Meeting
11. CHI Vice President Provides Testimony On Patient, Physician Notification of Biosimilar Substitution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... acquired Kendall Research Systems, LLC (KRS) clinical development program. KRS is ... interface technology for research and clinical applications. The terms of the transaction were ...
(Date:2/22/2017)... 2017 Scientists propose in Nature ... in Gaucher and maybe other lysosomal storage diseases as ... than current therapies. An international research team ... which also included investigators from the University of Lübeck ... Feb. 22. The study was conducted in mouse models ...
(Date:2/22/2017)... ... 22, 2017 , ... LabRoots , the leading provider ... world, is pleased to announce the 2nd annual Precision Medicine Virtual Conference. The ... conference focused on the development and advancements in precision medicine. , Precision Medicine ...
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, ... trait and seed provider, and Arcadia (Arcadia ... that develops and commercializes agricultural productivity traits and nutritional products, today ... corn biotechnology product developed in China to ... regulatory trials. ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):